|Videos|September 14, 2016

Importance of Outbreak Preparedness in the Healthcare Setting

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, describes the importance for hospital staff to be prepared for outbreaks.

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, describes the importance for hospital staff to be prepared for outbreaks.

Interview Transcript (slightly modified for readability)

“When the Ebola outbreak was occurring, as a system we have a very advanced [emergency] management [and emergency] planning division, we worked with them and we trained well over 500 staff members in level 3 PPE, which was above the needed protective gear level. [We] treated 100% of all of our [emergency] department staff: physicians, nurses, everyone in level 1 and level 2 PPE. We did mass training to make sure [that] we had everyone up to par, and we continue to do training, depending on the personnel folks that did the level 3 training. Every few months [the] have to still demonstrate competency, so we rotate around and have trainers go and test people that went through the original training. Our specialized treatment team, which we put together at that time to respond to any[thing], those folks were train at a much higher level. We have both our [emergency] management people that will respond to a scene of a potential incident or need, as well as our internal ED people, trained up to speed.

The other thing that happened during the Ebola time, was that there wasn’t enough [equipment]. We were lucky [that] we had a huge stockpile, but a lot of facilities struggled with having the appropriate equipment even available. There was, all of a sudden, a scarcity of the appropriate mask[s] and gowns and things of that nature. We were actually lending stuff to other health systems because we had enough of it on hand. Most places were doing level 1, level 2 training, [whereas] we trained a lot of people up to level 3.

I think [that] the message to the staff is that it’s not just about Ebola; it’s about anything. I think [that] they all realize that it protects them, it protects their families, their patients. We don’t want anybody to be in a situation where they’re trying to figure it out [in] real time, when they have something in front of them and they’re putting stuff on the wrong way, or they have exposed skin, or they contaminate themselves getting out of the equipment. It's just critical that everybody knows [about emergency management]. This is the job we all chose and we just have to be able to do it safely, so [that] we don’t put ourselves, our famil[ies], or our patients at risk.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.